Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Onishchenko, Dmitry [1 ]
Dunyak, James [2 ]
Masson, Eric [2 ]
Helmlinger, Gabriel [2 ]
Peskov, Kirill [1 ]
Tomkinson, Helen [4 ]
Stanski, Donald [3 ]
Al-Huniti, Nidal [2 ]
机构：
[1] M&S Decis LLC, Moscow, Russia
[2] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Waltham, MA USA
[3] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Gaithersburg, MD USA
[4] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Cambridge, England
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-091
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [1] Joint model of longitudinal tumor size and overall survival (OS) in non-small cell lung cancer (NSCLC): A Bayesian approach
    Al-Huniti, Nidal
    Xu, Hongmei
    Zhou, Diansong
    Edlund, Helena
    Aksenov, Sergey
    Helmlinger, Gabriel
    Dunyak, James
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [2] Bayesian formulation of a joint model of longitudinal tumor size and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC)
    Al-Huniti, Nidal
    Dunyak, James
    Aksenov, Sergey
    Zhou, Diansong
    Xu, Hongmei
    Masson, Eric
    Helmlinger, Gabriel
    Edlund, Helena
    Stanski, Donald
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S141 - S141
  • [3] DYNAMIC PREDICTION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN NON-SMALL CELL LUNG CANCER (NSCLC) USING TUMOR SIZE: A LONGITUDINAL JOINT MODELING APPROACH.
    Al-Huniti, N.
    Onishchenko, D.
    Xu, H.
    Zhou, D.
    Masson, E.
    Helmlinger, G.
    Tomkinson, H.
    Abdallah, K.
    Dunyak, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S55 - S55
  • [4] Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients
    Tong, Xiao
    Dunyak, James
    Zhou, Diansong
    Carlile, David
    Tomkinson, Helen
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Xu, Hongmei
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Identification of prognostic and predictive factors for durvalumab efficacy by modeling of tumor response and overall survival (OS) in patients with non-small cell lung cancer (NSCLC)
    Zheng, Y.
    Narwal, R.
    Jin, C.
    Baverel, P.
    Gupta, A.
    Mukhopadhyay, P.
    Higgs, B. W.
    Roskos, L.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [6] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [7] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
    Martin Faehling
    Birgit Schwenk
    Sebastian Kramberg
    Sabine Fallscheer
    Matthias Leschke
    Jörn Sträter
    Robert Eckert
    [J]. Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2059 - 2066
  • [8] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
    Faehling, Martin
    Schwenk, Birgit
    Kramberg, Sebastian
    Fallscheer, Sabine
    Leschke, Matthias
    Straeter, Joern
    Eckert, Robert
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (10) : 2059 - 2066
  • [9] Non-examination of lymph nodes (LN) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients.
    Jemal, Ahmedin
    Lin, Chun Chieh
    Smeltzer, Matthew
    Osarogiagbon, Raymond U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
    Genova, C.
    Rijavec, E.
    Rossi, G.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Grossi, F.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345